Key Stories Impacting REGENXBIOHere are the key news stories impacting REGENXBIO this week:Get REGENXBIO alerts:Positive Sentiment: Q2 results exceeded expectations. Neutral Sentiment: Barclays maintained an “Equal Weight” rating but raised or reaffirmed a $12 price target, implying roughly 15% upside from the cited share price. Barclays Rating Updatebut raised or reaffirmed a $12 price target, implying roughly 15% upside from the cited share price. Zacks Research cut REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. REGENXBIO Price PerformanceThe stock has a fifty day moving average price of $9.94 and a 200 day moving average price of $9.42.